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Background: TMPRSS4 is a membrane-anchored protease involved in cell migration and invasion in different cancer types
including lung cancer. TMPRSS4 expression is increased in NSCLC and its inhibition through shRNA reduces lung metastasis.
However, molecular mechanisms leading to the protumorigenic regulation of TMPRSS4 in lung cancer are unknown.
Methods: miR-205 was identified as an overexpressed gene upon TMPRSS4 downregulation through microarray analysis. Cell
migration and invasion assays and in vivo lung primary tumour and metastasis models were used for functional analysis of miR-205
overexpression in H2170 and H441 cell lines. Luciferase assays were used to identify a new miR-205 direct target in NSCLC.
Results: miR-205 overexpression promoted an epithelial phenotype with increased E-cadherin and reduced fibronectin.
Furthermore, miR-205 expression caused a G0/G1 cell cycle arrest and inhibition of cell growth, migration, attachment to
fibronectin, primary tumour growth and metastasis formation in vivo. Integrin a5 (a proinvasive protein) was identified as a new
miR-205 direct target in NSCLC. Integrin a5 downregulation in lung cancer cells resulted in complete abrogation of cell migration,
a decreased capacity to adhere to fibronectin and reduced in vivo tumour growth, compared with control cells. TMPRSS4
silencing resulted in a concomitant reduction of integrin a5 levels.
Conclusion: We have demonstrated for the first time a new molecular pathway that connects TMPRSS4 and integrin a5 through
miR-205 to regulate cancer cell invasion and metastasis. Our results will help designing new therapeutic strategies to inhibit this
novel pathway in NSCLC.
Lung cancer is a critical problem in public health. It represents the
most frequent tumour type in men and the second in women, and
the 5-year survival rate remains inferior to 20% (Jemal et al, 2010).
More than 60% of NSCLC patients present locally advanced,
unresectable or metastatic (stage III/IV) tumours at the time of
diagnosis, which fatally concludes in death within few months after
diagnosis. In spite of the advent of targeted therapies, which has
been a breakthrough for NSCLC management, only a small
percentage of patients will benefit from them. Therefore, there is a
need for identifying new potential therapeutic targets against which
more effective treatments may be developed.
Altered expression of proteases is currently considered as a
hallmark of cancer, as malignant cells need proteolytic activities to
promote growth, motility and invasion (Roy et al, 2009). Type II
transmembrane serine proteases (TTSPs) are characterised by the
presence of an N-terminal transmembrane domain that anchors
these proteases to the plasma membrane. TTSPs include 18
members that can be divided into four groups. Examples of TTSPs
related to cancer are hepsin, matriptase, HAT/DESC and
TMPRSS4 (Szabo and Bugge, 2008).
TMPRSS4 comprises a short N-terminal cytoplasmic domain, a
transmembrane domain and a large extracellular domain that
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contains the catalytic activity. TMPRSS4 is synthesised as an
inactive zymogen that needs to be activated (Netzel-Arnett et al,
2003). However, both the substrates and activators of this serine
protease are largely unknown. TMPRSS4 participates in the
regulation of cellular signalling events at the plasma membrane
and in the extracellular matrix (Hooper et al, 2001). TMPRSS4 is
upregulated in pancreatic, colon, lung, ovary and thyroid cancers,
where it has been suggested as a diagnostic marker (Kebebew et al,
2005). In a previous work, we demonstrated that TMPRSS4 is
highly expressed in lung tumours compared with normal lung,
particularly in squamous cell carcinomas (SCC) as compared with
adenocarcinomas (AC). We also demonstrated that high TMPRSS4
mRNA levels in SCC are associated with poor prognosis (Larzabal
et al, 2011). Moreover, a knockdown strategy to reduce TMPRSS4
levels in lung tumour cells resulted in a significant impairment of
metastasis in animal models (Larzabal et al, 2011).
Studies of biological activity in colon cancer have reported that
elevated TMPRSS4 expression induces epithelial-to-mesenchymal
transition (EMT) of cancer cells and promotes metastasis (Jung
et al, 2008; Kim et al, 2010). Further analysis of TMPRSS4-
mediated signalling in colon cancer cells suggested that multiple
downstream signalling pathways are activated. These included Src,
ERK1/2, AKT, FAK and Rac1, resulting in E-cadherin down-
regulation and induced expression of integrin a5b1, a critical
adhesion molecule involved in the acquisition of an EMT
phenotype and cell motility (Maschler et al, 2005). Inhibition of
PI3K or Src with specific compounds decreases cell invasiveness
and actin rearrangement mediated by TMPRSS4. Moreover,
functional blockade of integrin a5b1 demonstrated that this
integrin has an important role in TMPRSS4-mediated effects
(Kim et al, 2010). In spite of these data, the molecular regulation of
TMPRSS4 in cancer cells is poorly understood.
The aim of this study was to identify molecular mechanisms
involved in the protumorigenic regulation of TMPRSS4 in NSCLC.
Through a microarray analysis, we discovered that the miR-205
gene (MIR205HG) was consistently overexpressed upon TMPRSS4
downregulation. We demonstrate here that overexpression of
miR-205 promotes an epithelial phenotype and inhibits tumour
cell migration and metastasis formation in lung cancer models.
Moreover, we have identified integrin a5b1 (a proinvasive protein)
as a new miR-205 direct target in NSCLC; we also show a novel
molecular mechanism that connects TMPRSS4 with integrin a5b1
through miR-205.
MATERIALS AND METHODS
Cell culture. All human lung cancer cell lines were obtained from
the American Type Culture Collection (Manassas, VA, USA) and
were maintained in RPMI (Sigma, Madrid, Spain) with 10% fetal
bovine serum (Thermo Scientific, Waltham, MA, USA) and 1%
penicillin-streptomycin (Lonza, Basel, Switzerland), at 37 1C and
5% CO2 atmosphere.
H358 and H441 cell clones with a reduction of TMPRSS4
(shTMP4) and their corresponding controls (carrying the empty
vector; shCtrl) were previously described by our group (Larzabal
et al, 2011).
Immortalised normal human bronchial epithelial cells (HBECs)
have been previously characterised (Ramirez et al, 2004). These cell
lines were kindly provided by Dr J.D. Minna (University of Texas
Southwestern Medical Center, Dallas, TX, USA). Cells were
maintained in keratinocyte serum-free medium supplemented
with human recombinant epidermal growth factor (EGF) and
bovine pituitary extract (Life Technologies, Carlsbad, CA, USA).
miRNA transfection. H2170, H441 and A549 cell lines were
transfected with miRNASelect pEP-miR Null control vector or
miRNASelect pEP-hsa-miR-205 vector (Cell Biolabs, San Diego,
CA, USA) using GeneJuice reagent (Merck Millipore, Darmstadt,
Germany). Transfected cell clones were selected with puromycin
(2 mgml 1).
Integrin a5 inhibition. We used integrin a5 shRNA lentiviral
particles (Santa Cruz Biotechnology, Dallas, TX, USA) to inhibit
integrin a5 expression in the H2170 cell line. Infection with shRNA
was performed with polybrene according to the manufacturer’s
protocol. Stable clones were selected with 1mgml 1 puromycin. The
integrin a5 expression was analysed by western blot and qPCR.
RNA extraction and quantitative real-time PCR. RNA isolation
and qPCR was carried out as previously described (Larzabal et al,
2011). Assays were performed to quantify mRNA levels of human
E-cadherin, fibronectin, ZEB1/ZEB2 and integrin a5. The primer
sequences are shown in Supplementary Table 1.
To detect mature miR-205 expression, TRIzol reagent (Invitrogen,
Carlsbad, CA, USA) was used to isolate total RNA. For the
quantification of this miRNA, stem-loop RT of 20 ng total RNA
was run using the TaqMan MicroRNA Reverse Transcription kit
(Applied Biosystems, Foster City, CA, USA) with specific primers
for miR-205 and RNU48 as endogenous control (Applied
Biosystems). Subsequently, the qPCR amplifications were
performed with TaqMan 2 Universal PCR Master Mix, No
AmpErase UNG (Applied Biosystems) and specific primers for
miR-205 and RNU48 (Applied Biosystems). Relative miR-205
levels were normalised to RNU48 expression. Data are given as
2DDCt or 2DCt.
Proliferation and clonogenic assays. To determine proliferation
of H2170 and H441 cells and their miR-205 expressing clones,
1200 cells per well were seeded in 96-well plates. Ninety-six hours
after plating, MTT assays were performed following the manu-
facturer’s protocol (Sigma).
To evaluate the clonogenic potential of miR-205 expressing
clones, 500 cells per well were plated into six-well plates in
adherent conditions. After 10 days in culture, colonies were fixed
with 4% buffered formalin (Panreac, New Jersey, NY, USA) and
stained with 2% crystal violet. The number of colonies per well was
determined.
Anchorage-independent growth assay. Soft-agar assay was used
to determine the ability of miR-205-expressing clones to grow
under anchorage-independent conditions. Each well of a six-well
plate was coated with culture medium containing 0.6% agarose.
Upon solidification, a layer of 0.3% agar in culture medium
carrying 2000 cells per well was placed on top of the agarose.
Colonies were stained with MTT and counted after 2 weeks of
incubation.
Cell cycle analysis. For cell cycle distribution analysis, adherent
and floating cells were fixed in 70% ethanol for 1 h (or until
analysis) at 4 1C. Cells were then rehydrated in PBS, treated with
RNase A (0.2mgml 1, Sigma) for 1 h at 37 1C and stained with
7AAD (0.02mgml 1, Sigma). Cells were analysed in a flow
cytometer (FACSCalibur, BD). Percentages of cells in the Sub-G0,
G0/G1, S and G2/M phases were determined.
Migration assays. Migration assays were conducted in a Boyden
chamber for the H2170 and A549 cell lines. A total of 15 000 cells
per well in serum-free medium were seeded in the upper transwell
of 24-well plates (Costar, Tewksbury, MA, USA). Medium with
10% of serum was used as a chemoattractant and was placed in the
lower compartment. After 48 h, cells in the top chamber were
wiped with a cotton swab, and cells in the lower compartment were
fixed with 4% formalin and stained with crystal violet. The number
of migratory cells was evaluated with a Leica DMIL LED
microscope using the LAS EZ software (Leica Microsystems,
Wetzlar, Germany).
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H441 cells did not migrate through the transwell in Boyden
chambers (unpublished observations). For this reason, we
examined migration of this cell line with an in vitro model of
wound healing. Cells were grown until confluence, and a 20-p
micropipette tip was used to create a linear scratch in the
monolayer. Pictures of the wounds were taken right after the
scratching and 24 h later with a Nikon Eclipse photomicroscope
(Nikon, Kingston, UK) using the ACT-2U1.6 software (Nikon).
The empty surface between the wound edges was measured with
the TScratch analysis software (Zurich, Switzerland).
Adhesion assay. Single-cell suspensions were rinsed with serum-
free medium supplemented with 0.5% BSA, and 30 000 cells per
well were seeded in 96-well plates precoated with 3% BSA
(control), fibronectin (20 mgml 1 per well) or collagen type I
(50 mgml 1 per well). After 30min incubation to let cells adhere to
the substrates at 37 1C, wells were washed with PBS to remove the
floating cells. Attached cells were fixed in 4% paraformaldehyde
and stained with 0.5% toluidine blue. To obtain the adherent cell
number, stained cells were treated with 1% SDS, and the
absorbance at 595 nm was measured using a Sunrise spectro-
photometer (Tecan, San Jose, CA, USA).
E-cadherin and fibronectin immunofluorescence. Control cells
and miR-205-expressing cell clones were grown in slide chambers
until confluence. Cells were fixed by immersion in acetone:metha-
nol (1 : 1) solution for 10min at  20 1C. Then, non-specific
binding sites were blocked with 2% BSA, and slides were incubated
with primary anti-E-cadherin (BD Bioscience, San Jose, CA, USA)
or anti-fibronectin (Abcam, Cambridge, UK) antibodies at 1 : 100
dilution for 2 h at room temperature. Slides were then incubated in
darkness with the secondary antibody (488 Alexa Fluor dye,
Invitrogen) for 1 h at room temperature. For nuclei staining,
samples were incubated with 0.1mgml 1 DAPI. A hydrophilic
mounting medium (SlowFade antifade) was used, and coverslips
were sealed with nail polish. For visualisation and acquisition of
images, an Axio Imager Z1 (ZEISS) epifluorescence microscope
equipped with a CoolSnap CCD camera was used.
Microarray hybridisation and bioinformatic analysis. Tran-
scriptional profiling was done with the Affymetrix Human Gene
1.0 ST microarray according to the manufacturer’s protocol. Both
background correction and normalisation were done with RMA
(Robust Multichip Average) algorithm (Irizarry et al, 2003). Then,
a filtering process was performed to eliminate low expression probe
set intensities for each probe, recorded in CEL files and data were
analysed. The analysis of significant gene expression changes in
shTMP4 samples compared with expression in control cells was
performed by Z-score transformation of fold-change distributions
(Cheadle et al, 2003). A threshold of |z|42.3 (P-valueo0.01)
was set to select genes for further analysis. The selection of genes
differentially expressed in miR-205-overexpressing cells with
respect to control cells was performed using the criteria based on
the fold-change value. Probe sets were selected as significant using
a cutoff value of 2. The set of differentially expressed genes was
compared with the miRNA-predicted targets stored in public
databases (Betel et al, 2008; Griffiths-Jones et al, 2008; Friedman
et al, 2009). As a result, putative microRNA target genes with
altered expression were identified.
Western blotting. Protein extraction and western blot were
carried out as previously described (Ponz-Sarvise et al, 2011).
The primary antibodies (diluted at 1 : 1000) were as follows: anti-
human ITGa5 (Sigma), anti phospho-Src (Cell Signaling, Danvers,
MA, USA) and anti-Src (Cell Signaling). An anti-human b-actin
antibody (Sigma) at 1 : 10 000 dilution was used as a loading
control. Horseradish peroxidase-labelled secondary antibodies
(GE Healthcare, Waukesha, WI, USA) against the corresponding
primary antibodies were used. Immunoreactive bands were
visualised by a chemiluminescent method using the Lumi-
lightPLUS kit (Roche, Palo Alto, CA, USA).
Generation of H2170 TGL-expressing cells for in vivo imaging.
Amphopack-293 packaging cells (Clontech, Madison, WI, USA)
cultured with DMEM and 10% fetal bovine serum were transfected
with the pSFGNESTGL purified plasmid as previously described
(Larzabal et al, 2011). After 48 h in culture, virus containing
supernatant was added to parental H2170 cells and H2170-miR-
205-expressing cell clones. To increase the efficiency of infection,
7.5 mgml 1 polybrene (Sigma) was added to the virus containing
supernatants. Vector containing GFPþ cells were sorted by FACS
(FACSAria Ilu). More than 90% of the cells were confirmed to
express the reporter construct (Supplementary Figure 1A).
In vivo experiments. Animal studies were carried out according to
the ethical guidelines established by our Institution (University of
Navarra), under an approved animal protocol (069/11). For the
lung metastasis model, 1.5 106 H2170 cells containing the
control vector (miR-Scr) or the miR-205 overexpressing clones
(miR-205#2 or miR-205#3) infected with the TGL reporter vector
were injected in the tail vein in NOD SCID ILRb2 null (NSG)
mice. Four mice per group were used. Lung tumour development
was monitored by detection of luciferase photon emission, using a
Xenogen (Xenogen Inc., Alameda, CA, USA) (IVIS 100 series)
living image system. Anaesthetised mice were injected intraper-
itoneally with 3mg of D-Luciferin (Promega, Fitchburg, WI, USA)
diluted in PBS, 5min before light caption. The image acquisition
time was in the range of 5min. Data analyses were performed with
the Living Image Igor Pro (Xenogen) software coupled to the IVIS
system. Photon counts were calculated for each mouse using a
circular region of interest.
To study the effect of miR-205 on primary tumour growth,
10 106 H2170 cells and their corresponding miR-205-over-
expressing clones (miR-205#2 or miR-205#3) were injected
subcutaneously into the flanks of the mice in a 1 : 1 PBS/Matrigel
solution (BD). A similar experiment was conducted to assess
whether knockdown of ITGa5 (shITGa5 H2170 cells) would
decrease primary tumour growth with respect to controls. Tumour
volumes were calculated with the formula: V¼ length (width)2/2.
Immunohistochemistry. Tumours were excised, fixed, paraffin-
embedded and cut in 5mm thick sections, which were placed on
slides. Slides were deparaffinised, rehydrated and treated for
12min with 3% H2O2 (Panreac) in water to quench the
endogenous peroxidase activity. For caspase-3, antigen retrieval
was performed by heating the sections in a microwave oven in
1mM EDTA (pH 8). Tissues were then blocked with normal goat
serum in TBS (30min, RT). Incubation with the following primary
antibodies was done overnight at 4 1C: anti-cleaved caspase-3
Asp175 (Cell Signaling) at 1 : 200 dilution, anti-PCNA (Clone
PC10; Dako, Glostrup, Denmark) at 1 : 400 dilution and anti-
integrin a5 (Sigma) at 1 : 50 dilution. After incubation with
Envision anti-rabbit or anti-mouse system (Dako), peroxidase
activity was developed with DAB (3,30-diaminobenzidine; Dako).
Finally, slides were counterstained with haematoxylin, dehydrated
and mounted with DPX (VWR).
Renilla luciferase assay. The renilla luciferase constructs with the
30-untranslated region (UTR) of ITGa5 were made with the
following oligonucleotides:
ITGa5 30UTR-F: 50-CTAGAGAGGAGCTGGGGATCCCTCCG
CCCTGTGAAGGAACCATGCACTGTGAAGGACCCTTGTGC-30
ITGa5 30UTR-R: 50-GGCCGCACAAGGGTCCTTCACAGTGC
ATGGGGCGGAGGGATCCCCAGCTCCTCT-30
ITGa5-30UTR-Mut-F: 50-CTAGAGAGGAGCTGGGGATCCT
CAACCCCCAGACACTTGAGGTAGCCCTTGTGC-30
ITGa5-30UTR-Mut-R: 50-GGCCGCACAAGGGCTACCTCAA
GTGTCTGGGGGTTGAGGATCCCCAGCTCCTCT-30
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These oligonucleotides contain the target site sequence or the
mutated version (indicated in bold letters), which is complemen-
tary to the seed sequence of miR-205. Hybridised oligonucleotides
were ligated into the XbaI—NotI site of the renilla reporter vector
(pRL-SV40; Promega). GeneJuice reagent was used to co-transfect
the renilla- ITGa5-30UTR vector or the Renilla- ITGa5-30UTR-
mut, and a control vector containing firefly luciferase (pGL3-basic;
Promega), together with either pre-miR-205 or scramble pre-
cursor-miR vectors. Renilla luciferase activity was measured 48 h
after transfection with the Dual-Luciferase System (Promega) in a
Berthold Luminometer (Lumat LB 9507).
Statistical analysis. Statistical differences between groups were
examined with the Student’s t-test or ANOVA for unpaired
parametric variables and the Mann–Whitney U-test or Kruskal-
Wallis for unpaired non-parametric variables. Normality was
analysed with the Shapiro-Wilks test. Data were processed with the
SPSS statistical software (SPSS-IBM Inc., Chicago, IL, USA)
(version 17.0 for Windows SPSS) and GraphPad Prism 5 software
(GraphPad Software Inc., San Diego, CA, USA). P-values lower
than 0.05 were considered as statistically significant.
RESULTS
TMPRSS4 knockdown upregulates miR-205 expression. Previous
studies have shown that TMPRSS4 has a role in cell migration and
invasion (Kim et al, 2010). We have demonstrated that TMPRSS4
expression is increased in NSCLC and that its inhibition through
shRNA reduces lung metastasis (Larzabal et al, 2011). Because
molecular mechanisms activated by TMPRSS4 are unknown,
we used an shRNA strategy to knockdown this protease in H358
and H441 cells, in search of genes with an altered expression.
Clones H358 shTMP4-2 and shTMP4-3 and H441 shTMP4 (with a
reduced TMPRSS4 expression) were selected for the microarray
analysis. We have previously shown that these clones have reduced
proliferative and migratory ability compared with their respective
controls (H358 shCtrl and H441 shCtrl) (Larzabal et al, 2011).
A list of 287 probes was found to be deregulated by 4two-fold
in the three cell clones analysed. From those, 176 probes
corresponded to non-annotated sequences. We then focused our
analysis in those genes whose expression trend was the same
(either upregulation or downregulation) in the three clones
(Figure 1A). Twenty-nine genes followed this pattern (12 of them
overexpressed and 17 of them underexpressed). As expected,
TMPRSS4 was one of the downregulated genes of this set. Other
downregulated genes that have a role in cancer cell adhesion
included DDR1 and CLEC18A. DDR1 has been shown to promote
lung cancer metastasis to the bone, and its expression correlates
with poor prognosis in NSCLC patients (Valencia et al, 2012).
One of the upregulated genes found in the list was MIR205HG.
This microRNA has been described as a tumour suppressor gene in
different tumour types (Song and Bu, 2009; Wu et al, 2009; Majid
et al, 2011), a reason whereby we decided to further study its role
in lung cancer. miR-205 expression in H358 and H441 shCtrl and
shTMP4 cell clones was validated by qPCR (Supplementary
Figure 1B).
miR-205 is downregulated in lung cancer cell lines. We first
determined mRNA levels of miR-205 in a panel of immortalised
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Figure 1. (A) Hierarchical cluster diagram of differentially expressed genes in H358 and H441 shTMP4 cell clones compared with their respective
controls (shCtrl). (B) Expression of miR-205 by qPCR in immortalised human lung cells (HBEC) and in lung cancer-derived cell lines. The RNA
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non-malignant human lung cells and human lung cancer cell lines.
Cancer cell lines did not express miR-205 (or had very low
expression, as in the case for H358 cells) in comparison with
immortalised HBEC cells (Figure 1B and Supplementary Table 2),
suggesting a tumour suppressor role for miR-205 in lung cancer.
miR-205 regulates cell proliferation, cell cycle progression and
anchorage-independent growth in lung cancer cell lines. The
effects of miR-205 on lung cancer were studied by overexpressing
miR-205 precursor molecules (pre-miR-205) in H2170 and H441
cell lines. Overexpression was confirmed by real-time PCR, and
two clones for H2170 (miR-205#2 and #3) and for H441 (miR-205#3
and #4) were selected for functional assays (Supplementary
Figures 1C and D).
Initially, we assessed whether ectopic expression of miR-205
had a biological effect on proliferation and clonogenicity. MTT
proliferation assays indicated that cell clones overexpressing
miR-205 had a reduction in cell proliferation rates compared with
cells transfected with scramble vector (miR-Scr) in both cell lines
tested (Figure 1C). Furthermore, the overexpression of miR-205
decreased clonogenic capacity of H2170 and H441 cell lines
(Figure 1D). These data indicate that miR-205 inhibits cell growth
in lung cancer cell lines. As anchorage-independent growth is
strongly correlated with tumorigenicity, we then determined whether
miR-205 would alter cell growth in soft agar. H2170 cell clones were
plated in soft agar and incubated for 2 weeks before counting the
number of colonies. As shown in Figure 2A, the ability to form
colonies was almost abolished in miR-205-overexpressing clones
compared with scramble control. The same results were observed
in the H441 cell line (Supplementary Figure 1E).
A cell cycle analysis by flow cytometry was performed to determine
whether the decrease in cell proliferation due to miR-205 upregulation
was associated with a cycle arrest. Overexpression of miR-205
produced a significant increase in the percentage of cells in the
G0/G1 phase (from 56.44±1.72% to 66.03±1.77%; Po0.05), along
with a decrease in the S phase (Figure 2B), indicating that miR-205
induced a cell cycle arrest in the H2170 cell line. Similar results
were observed in the H441 cell line (Supplementary Figure 1F).
miR-205 inhibits cell migration and adhesion to fibronectin and
promotes an epithelial phenotype in lung cancer cells. We next
investigated whether miR-205 would modify cell migration in lung
cancer cells. For this purpose, H2170 control cells or clones with
elevated miR-205 levels were subjected to a migration assay.
As shown in Figure 2C, 48 h after plating, upregulation of miR-205
completely blocked the ability of cells to migrate. Migration assays
in Boyden chamber could not be performed with the H441 cell line
because, in our hands, these cells did not migrate through the
transwells. To further confirm the effect of miR-205 on migration
through transwells, A549 cells with miR-205 overexpression or
control cells (carrying the empty vector) were also used. As shown
in Supplementary Figure 1G, similar results to those found for
H2170 cells were obtained. In addition, as an alternative to this
assay using H441 cells, an in vitro wound healing assay was
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proportion of cells in this phase and a decrease in the S phase. (C) Migration of H2170 cells in Boyden chambers was strongly reduced by
overexpression of miR-205. (D) Migration of H441 cells in wound healing assays was impaired as well in clones with high miR-205 levels.
(E) Adhesion assay of H2170 miR-Scr, miR-205#2 and miR-205#3 clones to fibronectin (FNC). BSA was used as a negative control. Data and error
bars show mean±s.d. *Po0.05. **Po0.01. All these assays were repeated at least three independent times.
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performed to analyse migration in these cells. Figure 2D and
Supplementary Figure 2A show that overexpression of miR-205
caused a reduction in the ability of H441 cells to migrate.
To study the effects of miR-205 on cell–matrix adhesion,
we cultured H2170 cells on different substrates. miR-205 over-
expression decreased cell adhesion to fibronectin (Figure 2E) but
not to collagen type I (Supplementary Figure 2B). A similar
tendency was found for H441 cells, although results did not reach
statistical significance (data not show).
Different studies have demonstrated that miR-205 regulates
EMT by targeting ZEB2 (Gandellini et al, 2009; Matsushima et al,
2011). As shown in Figure 3A, ZEB1 and ZEB2 mRNA levels were
strongly reduced in miR-205-overexpressing cells. The analysis of
EMT markers by qPCR and immunofluorescence revealed a
marked increase in E-cadherin along with a pronounced decrease
in fibronectin in H2170 cells with miR-205 overexpression
(Figures 3B–D). The effect of miR-205 on E-cadherin and
fibronectin expression was similar (although less remarkable) in
H441 cells compared with H2170 cells (Supplementary Figures 2C
and D). These results show that miR-205 inhibits EMT and cell
motility and promotes an epithelial phenotype.
miR-205 reduces primary tumour growth and lung metastasis.
An in vivo assay was performed to investigate the role of miR-205
on primary tumour growth. Overexpression of miR-205 resulted in
a significant reduction in tumour volumes (Po0.05) in animals
xenotransplanted with both miR-205#2 and miR-205#3 H2170
clones, compared with mice injected with the miR-Scr control
(Supplementary Figure 2E).
Furthermore, we used a xenograft model to analyse the effect of
miR-205 on lung metastasis. In this case, animals were injected
with the H2170 clones in the tail vein and monitored by
bioluminescence until day 21. At day14th and 21st, a significant
increase in light emission in the H2170 miR-Scr group was
observed in comparison with the group injected with miR-205-
overexpressing cells (Figures 4A and B). At the end of the study
(day 21), animals were killed and lungs were examined for
metastatic lesions. Histological analysis confirmed a less tumour
burden in mice injected with cells that overexpressed miR-205
(Figure 4C). Immunohistochemical analysis of active caspase-3
revealed a higher proportion of apoptotic cells in tumours with
increased levels of miR-205 (Figure 4D).
Identification of miR-205 targets. We wanted to address the
molecular mechanism that causes miR-205 effects in lung cancer.
We hypothesised that miR-205 could reduce the expression of
target genes that induce EMT and inhibit cell invasion. To identify
miR-205 target genes, we compared mRNA expression profiles in
H2170 cells overexpressing miR-205 with those of controls (miR-Scr).
By microarray analysis, 796 probes displayed a 4two-fold
reduction in expression as a result of miR-205 upregulation
compared with controls. We searched within our gene list for
putative-predicted miR-205 targets using publicly available and
commonly used programs, such as TargetScan4, miRBase, PicTar
and miRanda. Among the candidates, many were related with
cell–cell and cell–matrix adhesion, cell invasion and metastasis
(a selected list can be found in Supplementary Table 3).
Importantly, one of the genes was integrin a5 (ITGa5), whose
30-UTR sequence had a perfect complementarity with the seed
sequence of miR-205 (Figure 5A).
Because ITGa5 is overexpressed in lung cancer (Dingemans
et al, 2010), it promotes invasion of cancer cells (Hood and
Cheresh, 2002) and its expression has been linked to TMPRSS4 in
colon cancer (Kim et al, 2010), we focused our attention on this
gene. We analysed whether endogenous ITGa5 mRNA and protein
levels decreased when miR-205 was overexpressed. We found that
miR-205 upregulation in H2170 or H441 lung cancer cells caused a
significant reduction in endogenous ITGa5 mRNA levels
(Figure 5B for H2170 cells and Supplementary Figure 2F for
H441 cells) and protein levels (Figure 5C for H2170 cells and
Supplementary Figure 2G for H441 cells). Moreover, Src signalling
pathway activated by integrins was downregulated in H2170 cells
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with an overexpression of miR-205 (Figure 5D). To determine
whether ITGa5 was a direct target of miR-205, we constructed
renilla-based reporters that contained the wild-type or the mutated
miR-205 target sequences of the ITGa5 30-UTR. Ectopic expression
of miR-205 inhibited the expression of the reporter vector
containing the wild-type sequence of ITGa5 30-UTR but not the
reporter vector containing the mutation of the seed-miR-205
binding site in the two cell lines tested (Figure 5E for H2170 cells
and Supplementary Figure 2H for H441 cells). These data show
that ITGa5 is a direct target of miR-205 and that miR-205 can
reduce ITGa5 mRNA and protein levels.
Knockdown of ITGa5 in lung cancer cells reduces cell migration
and cell–matrix adhesion. To examine whether ITGa5 expression
could mediate miR-205 regulation of cell proliferation and
migration, shRNAs against ITGa5 were transfected in H2170 cells.
ITGa5 shRNA efficiently decreased ITGa5 expression, as detected
by western blot analysis (Figure 6A). ITGa5 depletion resulted in a
complete abrogation of cell migration (Figure 6B) but no changes
in cell proliferation or cell cycle distribution were observed (data
not shown).
As integrins are major adhesion molecules involved in cell-ECM
interactions, we studied the effects of ITGa5 on cell–matrix
adhesion. After culture of these cells on different substrates,
we observed that ITGa5 levels modified the adhesiveness to
fibronectin (Figure 6C) but not to collagen type I (data not shown).
All these results provide evidence that inhibition of ITGa5 by
miR-205 is responsible, at least in part, for the antitumorigenic
effect observed in NSCLC cells with miR-205 upregulation.
Knockdown of ITGa5 inhibits tumour growth in vivo. To
further explore whether ITGa5 knockdown would be responsible
for the inhibition of tumour growth observed following miR-205
reconstitution, an in vivo experiment was performed. As shown in
Figure 6D, subcutaneous xenotransplantation of H2170 cells with
ITGa5 depletion caused a significant tumour shrinkage (Po0.05)
in comparison with control cells.
Relationship between TMPRSS4 and ITGa5 expression. Having
demonstrated that reduction of TMPRSS4 increases miR-205,
which targets ITGa5, we studied levels of ITGa5 in shTMP4 cell
clones. Figure 6E shows that, in agreement with previous results,
ITGa5 levels were lower in shTMP4 clones than in controls, in the
three cell lines tested. We also wondered whether there would be a
correlation between ITGa5 and TMPRSS4 expression in cell lines.
qPCR analysis for ITGa5 was conducted in 30 lung cancer cell lines
and its expression was compared with that of TMPRSS4 in our
previous publication (Larzabal et al, 2011). As shown in Figure 6F,
22 out of 30 cell lines expressed ITGa5. Eleven of the TMPRSS4
(þ ) cells expressed ITGa5 as well, but some TMPRSS4 ( ) cells
were positive for ITGa5 (Supplementary Table 4). This shows that
ITGa5 may be regulated by other proteins in addition to
TMPRSS4. On the basis of our findings, we propose a molecular
mechanism through which TMPRSS4, regulating miR-205 expres-
sion, can modulate ZEB1, ZEB2 and ITGa5 levels to inhibit EMT
and metastasis in lung cancer (Figure 7).
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DISCUSSION
TMPRSS4 has been shown to increase cell motility and invasion, to
induce EMT and to promote metastasis in different cancer models,
through multiple downstream signalling pathways involving ERK,
AKT, Src and Rac1 (Kim et al, 2010). TMPRSS4 is upregulated in
some cancer types, such as colon, pancreas, thyroid and lung
(Wallrapp et al, 2000; Kebebew et al, 2005; Kim et al, 2010;
Larzabal et al, 2011). Thus, this serine protease has emerged as a
promising diagnostic and therapeutic target in cancer. Nonetheless,
the molecular regulation of TMPRSS4 leading to these effects is still
unknown. In the present study, we have identified a new molecular
mechanism whereby TMPRSS4 regulates integrin a5 levels through
the expression of miR-205. Because ITGa5 is strongly involved in
the protumorigenic effects elicited by TMPRSS4, the data reported
here about this novel molecular axis will help designing therapeutic
strategies to inhibit this pathway. Moreover, in the present study
we confirm the tumour suppressor role of miR-205 in lung cancer.
In order to elucidate the mechanism of action elicited by
TMPRSS4 during EMT and metastasis formation, we conducted a
microarray analysis where we compared gene expression profiles
after TMPRSS4 inhibition in H358 and H441 lung cancer cell lines,
with those of mock-transfected cells. As expected, the majority of
genes with a differential expression were related with cell invasion
and motility, in keeping with the functional role described for this
serine protease in some tumour types (Jung et al, 2008; Kim et al,
2010). One of the upregulated genes was miR-205, a microRNA
that has been described as a tumour suppressor (Song and Bu,
2009; Wu et al, 2009; Majid et al, 2011).
MicroRNAs (miRs) are small, non-coding RNAs that negatively
regulate gene expression via translational repression or messenger
RNA degradation (Bartel, 2004). MicroRNAs are involved in
biologic and pathologic processes, including cell differentiation,
proliferation and apoptosis (Kloosterman and Plasterk, 2006).
Accumulating evidence indicates that deregulation of miRs is
associated with the development of human cancers and suggests a
causal role of miRs in tumour initiation and progression, as they
can function as oncogenes or tumour suppressors (Caldas and
Brenton, 2005; Chen, 2005). Recently, studies have shown that
miR-205 regulates EMT through the modification of E-cadherin
and other adhesion proteins (Bracken et al, 2009; Gibbons et al,
2009). Expression of the miR-200 family and miR-205 has been
shown to be reduced in cells undergoing EMT. These miRs act by
directly targeting the 30-UTR sequence of ZEB1 and SIP1 (Gregory
et al, 2008; Park et al, 2008). miR-205 has also been shown to
suppress metastatic spread of human breast cancer xenografts in
nude mice (Iorio et al, 2009) and to exert a tumour suppressor role
by targeting HER3 receptor and VEGF-A in breast cancer (Iorio
et al, 2009; Wu and Mo, 2009) and Src in renal cancer (Majid et al,
2011). In lung cancer, overexpression of miR-205 in cell lines
hinders cell migration and invasion (Song and Bu, 2009) and its
inhibition results in the acquisition of cancer stem cell and EMT
properties, which favors tumour progression (Tellez et al, 2011).
Consistent with these reports, we demonstrate that miR-205 was
markedly downregulated in lung cancer cell lines compared with
non-malignant HBEC lung epithelial cells. Its overexpression
strongly reduced cell proliferation and clonogenic survival and
caused G0/G1 cell cycle arrest. In addition, we show that forced
expression of miR-205 in lung cancer cells impaired migratory and
invasive capabilities. Furthermore, we demonstrate that miR-205
expression reduced lung metastasis formation and promoted an
epithelial phenotype by inducing E-cadherin and decreasing
fibronectin levels. However, the role of miR-205 in lung cancer
remains controversial, since some studies indicate a high expres-
sion of this miRNA in lung cancer compared with normal lung
tissue (Yanaihara et al, 2006; Markou et al, 2008; Lebanony et al,
2009). Interestingly, expression of miR-205 has been described as a
biomarker to distinguish between AC and SCC (Hamamoto et al,
2013; Jiang et al, 2013). It is worth noticing though, that exposure
of HBEC cells to tobacco carcinogens silences miR-205 expression
through epigenetic mechanisms, leading to a dedifferentiation
programme (Tellez et al, 2011). Moreover, epigenetic silencing of
miRNAs with tumour suppressor features, including miR-205, is
emerging as a common hallmark of human tumours (Lujambio
et al, 2008).
Each miRNA has the potential to target hundreds of genes,
which harbour sequences in their 30-UTRs that are complementary
to the seed region of the miRNA (Lim et al, 2005). Different targets
of miR-205 have been described including, as previously
mentioned, ZEB1 and SIP1 (Gregory et al, 2008), ERBB3 and
VEGF-A (Wu et al, 2009), LDL receptor protein 1 (Song and Bu,
2009) and PKCe (Gandellini et al, 2009). In the present study, we
have identified and validated for the first time ITGa5 as a new
target of miR-205 in cancer.
Integrins are a family of cell adhesion proteins that activate
diverse intracellular signalling molecules and reorganise the
actin cytoskeleton to regulate attachment, survival and motility
(Giancotti and Ruoslahti, 1999; Hood and Cheresh, 2002).
In NSCLC, expression of particular integrins has been shown to
predict the clinical course and prognosis of patients (Adachi et al,
2000; Gogali et al, 2004). ITGa5 binds to integrin b1 to give rise to
the a5b1 heterodimer. Fibronectin stimulates the proliferation of
lung cancer cells through a5b1 integrin receptor-mediated
signalling; thus knockdown of this integrin reduces tumour burden
(Roman et al, 2010). High expression of ITGa5 is associated with
lower overall survival in patients with early stages of NSCLC
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(Dingemans et al, 2010). Moreover, high ITGa5 levels have been
associated with poor prognosis in NSCLC patients with negative
lymph nodes (Adachi et al, 2000). We show here that 22 out of
30 lung cancer cell lines analysed expressed ITGa5. Furthermore,
inhibition of this integrin diminishes cancer cell migration,
adhesion and tumour growth. These data suggest that ITGa5
may constitute a target worth studying in patients with NSCLC.
A close relationship between acquisition of EMT features and
ITGa5 expression has been observed. Inhibition of E-cadherin in
ovarian cancer cells causes upregulation of ITGa5 (Sawada et al,
2008). ZEB2, a transcription factor that represses E-cadherin,
upregulates ITGa5 levels through cooperation with Sp1 to induce
EMT and invasion in cancer cells (Nam et al, 2012). In this line,
Kim et al (2010) pointed to TMPRSS4 as a new regulator of EMT
in colon cancer and suggested that Src, FAK and ERK, which are
major downstream effectors of integrins, appeared to be key
signalling molecules involved in cell invasion and in the cadherin
switch, presumably via regulation of ITGa5 expression.
In agreement with these results, we show a downregulation of
ITGa5 in H358, H441 and H2170 lung cancer cell lines with an
inhibition of TMPRSS4, which confirms the regulation of ITGa5
by TMPRSS4. Therefore, it appears that targeting the novel
TMPRSS4/miR-205/ITGa5 axis may be a promising strategy to
inhibit EMT and metastasis in NSCLC. In this regard, an antibody
targeting integrin a5b1 (volociximab, PDL Biopharma) has been
developed and is being currently tested in phase II clinical trials for
solid tumours (particularly for renal carcinoma).
In summary, our results provide evidence for the existence of a
new molecular connection between two membrane-anchored
proteins (ITGa5 and TMPRSS4) that cooperate to foster tumour
growth, metastasis and migration, through miR-205. This new
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intracellular signalling pathway appears to have an important role
in the development of lung cancer. TMPRSS4 blockade in tumour
cells causes an overexpression of miR-205, resulting in an
inhibition of the transcription factors ZEB1 and ZEB2, and ITGa5,
which leads to a loss of EMT features. This, in turn, decreases cell–
matrix interaction and cell invasiveness, hindering cell migration
and metastasis formation. Biological or pharmacological approaches
to block TMPRSS4 and ITGa5 may constitute an interesting novel
approach to inhibit lung cancer.
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